Exosome, the Next Small Thing: A Winning Strategy for Commercial Manufacturing

Behzad Mahdavi, Ph. D., MBA

Vice President Strategic Innovation & Alliances/ Chairman of the Board of Exosomics at Lonza

Create your free account now to watch this video and browse the entire executive library.
Sign Up
26:39

Successful development and commercialization of Exosomes-Based therapies require a scalable manufacturing platform in order to be able to meet market needs (QUANTITY) at acceptable COGS. This will ensure patient accessibility and deliver the desired ROI for therapy developers (COST). Furthermore and more importantly, the process must result in high quality material consisting of well-defined final exosome-based product (QUALITY). In this presentation, we cover these three important factors with a particular emphasis on characterization considered as a key critical element for successful development and commercialization.


Key Themes:



  • Strategy for manufacturing exosomes-based therapies

  • Importance of exosome characterization

  • How to build a successful integrated business case


Q/N delivers the info you need, from the people that know Learn More

On Demand

Education

An elite group of your peers relay insight & experience in an ever-growing video library, helping you make better business decisions.

Events

Invitation-Only

Executive-only events connect you to the people & solutions that simplify your path to success, learn why we’re the industry leader.

Innovative

Solutions

Coming Soon! We’ve made it quick & simple to connect with the best solutions on the market today. You’ll even get rewarded for it.

Become an Exclusive Member Today.